[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

NO20040860L - Farmasoytisk sammensetning som innbefatter lumiracoxib - Google Patents

Farmasoytisk sammensetning som innbefatter lumiracoxib

Info

Publication number
NO20040860L
NO20040860L NO20040860A NO20040860A NO20040860L NO 20040860 L NO20040860 L NO 20040860L NO 20040860 A NO20040860 A NO 20040860A NO 20040860 A NO20040860 A NO 20040860A NO 20040860 L NO20040860 L NO 20040860L
Authority
NO
Norway
Prior art keywords
lumiracoxib
pharmaceutical composition
composition including
pharmaceutical
including lumiracoxib
Prior art date
Application number
NO20040860A
Other languages
English (en)
Inventor
Anees Abdulquadar Karnachi
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20040860L publication Critical patent/NO20040860L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20040860A 2001-08-31 2004-02-26 Farmasoytisk sammensetning som innbefatter lumiracoxib NO20040860L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31638901P 2001-08-31 2001-08-31
PCT/EP2002/009701 WO2003020261A1 (en) 2001-08-31 2002-08-30 Pharmaceutical composition comprising lumiracoxib

Publications (1)

Publication Number Publication Date
NO20040860L true NO20040860L (no) 2004-04-22

Family

ID=23228840

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20040860A NO20040860L (no) 2001-08-31 2004-02-26 Farmasoytisk sammensetning som innbefatter lumiracoxib

Country Status (30)

Country Link
US (2) US20030114527A1 (no)
EP (1) EP1425005B1 (no)
JP (1) JP4636796B2 (no)
KR (1) KR100895551B1 (no)
CN (1) CN100406008C (no)
AR (1) AR036312A1 (no)
AT (1) ATE324883T1 (no)
AU (1) AU2002331094B2 (no)
BR (1) BR0212155A (no)
CA (1) CA2456604C (no)
CO (1) CO5560554A2 (no)
CY (1) CY1106137T1 (no)
DE (1) DE60211183T2 (no)
DK (1) DK1425005T3 (no)
EC (1) ECSP044986A (no)
ES (1) ES2263813T3 (no)
HK (1) HK1087336A1 (no)
HU (1) HUP0401429A2 (no)
IL (1) IL160375A0 (no)
MX (1) MXPA04001933A (no)
MY (1) MY137516A (no)
NO (1) NO20040860L (no)
NZ (1) NZ531342A (no)
PE (1) PE20030323A1 (no)
PL (1) PL367464A1 (no)
PT (1) PT1425005E (no)
RU (1) RU2329801C2 (no)
SI (1) SI1425005T1 (no)
WO (1) WO2003020261A1 (no)
ZA (1) ZA200400877B (no)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR030630A1 (es) * 2000-09-11 2003-08-27 Novartis Ag Composiciones farmaceuticas
GB0201520D0 (en) * 2002-01-23 2002-03-13 Novartis Ag Pharmaceutical uses
KR20040089654A (ko) * 2002-03-07 2004-10-21 노파르티스 아게 약제학적 조성물
NZ602496A (en) 2008-08-19 2013-09-27 Xenoport Inc Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions thereof, and methods of use
US20140093563A1 (en) * 2011-06-13 2014-04-03 Ranbaxy Laboratories Limited Febuxostat compositions
US10952968B2 (en) 2012-05-14 2021-03-23 Shionogi & Co., Ltd. Preparation containing 6,7-unsaturated-7-carbamoyl morphinan derivatives
EP2887935A1 (en) 2012-08-22 2015-07-01 XenoPort, Inc. Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof
JP2015527372A (ja) 2012-08-22 2015-09-17 ゼノポート，インコーポレイティド 副作用を低減させるモノメチルフマレートおよびそのプロドラッグの投与方法
EA018867B1 (ru) * 2012-11-01 2013-11-29 Лаборатория Тютор С.А.С.И.Ф.И.А. Способ получения фармацевтической композиции и продукт способа
US10179118B2 (en) 2013-03-24 2019-01-15 Arbor Pharmaceuticals, Llc Pharmaceutical compositions of dimethyl fumarate
US9302977B2 (en) 2013-06-07 2016-04-05 Xenoport, Inc. Method of making monomethyl fumarate
WO2014205392A1 (en) 2013-06-21 2014-12-24 Xenoport, Inc. Cocrystals of dimethyl fumarate
EP3041467A1 (en) 2013-09-06 2016-07-13 XenoPort, Inc. Crystalline forms of (n,n-diethylcarbamoyl)methyl methyl (2e)but-2-ene-1,4-dioate, methods of synthesis and use
ES2750323T3 (es) * 2014-01-10 2020-03-25 Johnson & Johnson Consumer Inc Método para la fabricación de un comprimido mediante radiofrecuencia y partículas recubiertas con pérdida
US9999672B2 (en) 2014-03-24 2018-06-19 Xenoport, Inc. Pharmaceutical compositions of fumaric acid esters
EP3162362A1 (de) * 2015-10-30 2017-05-03 Dr. Falk Pharma Gmbh Optimierte mesalazinhaltige hochdosistablette
US10493026B2 (en) 2017-03-20 2019-12-03 Johnson & Johnson Consumer Inc. Process for making tablet using radiofrequency and lossy coated particles

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2163111C (en) * 1993-06-08 2010-10-26 Peter Heinrich Stahl Process for the preparation of an oral solid dosage form containing diclofenac
CN1140267C (zh) * 1996-05-17 2004-03-03 麦克公司 治疗环加氧酶-2介导的疾病的每天一次的组合物
CO4960662A1 (es) * 1997-08-28 2000-09-25 Novartis Ag Ciertos acidos 5-alquil-2-arilaminofenilaceticos y sus derivados
SA99191255B1 (ar) * 1998-11-30 2006-11-25 جي دي سيرل اند كو مركبات سيليكوكسيب celecoxib
AR030630A1 (es) * 2000-09-11 2003-08-27 Novartis Ag Composiciones farmaceuticas

Also Published As

Publication number Publication date
EP1425005B1 (en) 2006-05-03
CA2456604C (en) 2011-02-08
HUP0401429A2 (hu) 2004-11-29
ZA200400877B (en) 2004-11-01
ECSP044986A (es) 2004-04-28
PL367464A1 (en) 2005-02-21
CO5560554A2 (es) 2005-09-30
RU2004109920A (ru) 2005-04-20
PE20030323A1 (es) 2003-05-12
RU2329801C2 (ru) 2008-07-27
AR036312A1 (es) 2004-08-25
ATE324883T1 (de) 2006-06-15
MXPA04001933A (es) 2004-06-15
JP4636796B2 (ja) 2011-02-23
KR20040031019A (ko) 2004-04-09
KR100895551B1 (ko) 2009-04-29
WO2003020261A1 (en) 2003-03-13
EP1425005A1 (en) 2004-06-09
US20030114527A1 (en) 2003-06-19
JP2005520785A (ja) 2005-07-14
SI1425005T1 (sl) 2006-12-31
NZ531342A (en) 2005-09-30
CN100406008C (zh) 2008-07-30
CN1728993A (zh) 2006-02-01
PT1425005E (pt) 2006-09-29
HK1087336A1 (en) 2006-10-13
CA2456604A1 (en) 2003-03-13
IL160375A0 (en) 2004-07-25
AU2002331094B2 (en) 2006-08-31
ES2263813T3 (es) 2006-12-16
CY1106137T1 (el) 2011-06-08
BR0212155A (pt) 2004-07-13
MY137516A (en) 2009-02-27
DE60211183D1 (de) 2006-06-08
DE60211183T2 (de) 2007-02-01
US20070231382A1 (en) 2007-10-04
DK1425005T3 (da) 2006-09-04

Similar Documents

Publication Publication Date Title
FI20011478A (fi) Farmaseuttinen koostumus
NO20035775L (no) 3-fluor-pyrrolidiner som anti-diabetesmidler
NO20033556L (no) Farmasöytiske formuleringer
NO20033384D0 (no) Farmasöytisk formulering
EE200300416A (et) Ravimvorm
DK1524266T3 (da) Farmaceutisk sammensætning
BR0210619A (pt) composição
EE200300589A (et) Ravimkoostised
NO20035627D0 (no) Farmasöytisk formulering
NO20040860L (no) Farmasoytisk sammensetning som innbefatter lumiracoxib
DE50209245D1 (de) Neuroprotektives medikament
FI20022128A (fi) Farmaseuttinen koostumus
ATE450652T1 (de) Wässrige zusammensetzung
ITTO20020744A0 (it) Composizione
EE200300465A (et) Püridoindolooni derivaatidel põhinevad farmatseutilised kompositsioonid
EE200300378A (et) Farmatseutiline kompositsioon
FI20012242A0 (fi) Uudet farmaseuttiset yhdisteet
ITTO20020745A0 (it) Composizione
FI5468U1 (fi) Farmaseuttinen koostumus
NO20041236L (no) Farmasoytisk formulering
SE0100847D0 (sv) Novel pharmaceutical composition
NO20016209D0 (no) Vitaminsammensetning
SE0100199D0 (sv) New formulation
SE0103116D0 (sv) Pharmaceutical combination
SE0102957D0 (sv) Pharmaceutical formulation

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application